A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.

Trial Profile

A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms LYMRIT37-01
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 12 Jun 2018 According to a Nordic Nanovector media release, based on the data from this trial US Food & Drug Administration (FDA) has granted Fast Track designation to Betalutin (177Lu-lilotomab satetraxetan) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least 2 prior systemic therapies.
    • 11 Apr 2018 Planned number of patients changed from 77 to 207.
    • 11 Apr 2018 Planned End Date changed from 1 Dec 2021 to 1 Mar 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top